Fig. 7

In a xenograft mouse model of breast cancer, the administration of HV-107 results in reduced metastasis formation but does not affect the primary tumor growth. Severe combined immune deficiency (SCID) mice were injected with GFP-MDA-MB-231 cells into the mammary fat pad and subsequently treated with either a vehicle solution (consisting of 12.5% cremophor, 12.5% ethanol, and 75% PBS) or HV-107 at a dosage of 5 mg/kg body weight, administered intraperitoneally five times a week beginning the tumor size reached 100 mm³. A The Rac activity in the tumors of the mice was analyzed using GLISA analysis. B Fluorescent images of the tumors were captured, and the relative integrated density of the tumors was quantified after 64 days of treatment. C, D Tumor growth measurement by caliper and intensity of fluorescence, analyzed as a function of days. The tumors that were surgically removed after the 64-day treatment course are presented. E Analysis of integrated density of metastatic foci formed in lungs and livers. F Average number of metastatic foci formed in lungs and livers. G Fluorescent images of metastatic foci formed on lungs and livers. Mean ± S.E. and significant differences from vehicle (*) are shown (p < 0.05). The number of mice in each treatment group was as follows: vehicle (N = 13), 5 mg/kg HV-107 (N = 13)